Conference
A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCIC CTG IND.154
Authors
Chi KN; Eisenhauer E; Siu L; Hirte H; Hotte SJ; Chia S; Knox J; Guns E; Powers J; Gleave ME
Volume
23
Pagination
pp. 3085-3085
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 2005
DOI
10.1200/jco.2005.23.16_suppl.3085
Conference proceedings
Journal of Clinical Oncology
Issue
16_suppl
ISSN
0732-183X